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Abstract
Background: Recently, rocuronium with subsequent use of sugammadex was proposed for electroconvulsive
therapy (ECT) as an alternative to succinylcholine. Because sugammadex is cleared via the kidney with no
metabolism, it is unknown that rocuronium-sugammadex use is safe in hemodialysis patients who received ECT.
Case presentation: In this case report, we used rocuronium with subsequent administration of sugammadex in a
69-year-old female, hemodialysis patient, scheduled for ten ECT sessions for severe major depression. In the initial
eight sessions, we tested the feasibility of rocuronium-sugammadex use for ECT. During the series of four ECT
sessions, we measured plasma concentrations for the sum of sugammadex and sugammadex-rocuronium complex
and observed whether possible residual sugammadex affected muscle relaxation during subsequent sessions of
ECT. The results showed the feasibility of rocuronium-sugammadex use as muscle relaxants for ECT in patients
undergoing hemodialysis. However, an accumulation of sugammadex did occur even after two sessions of
hemodialysis, and residual sugammadex decreased the effect of the rocuronium given in the subsequent ECT
sessions. Rocuronium-sugammadex was successfully utilized as muscle relaxants for ECT in this patient.
Conclusions: Our experience in this case may indicate that if succinylcholine is contraindicated, rocuronium-
sugammadex can be an alternative method for muscle relaxation during ECT in patients undergoing hemodialysis.
When this rocuronium-sugammadex procedure is used, the effect of residual sugammadex after hemodialysis on
the subsequently administered rocuronium should be considered.
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Background
Depression is common in patients undergoing hemodialysis
[1]. Several case reports have indicated that electroconvul-
sive therapy (ECT) is effective for treatment of depression
in hemodialysis patients [2–4]. Although succinylcholine
was used in those case reports [2–4], it may cause serious
adverse effects such as hyperkalemia and severe bradycardia
[5] and is contraindicated in patients with closed-angle
glaucoma, susceptibility to malignant hyperthermia, neuro-
leptic malignant syndrome, and plasma cholinesterase
deficiency [5–8]. Recently, rocuronium with subsequent
use of sugammadex was proposed for ECT as an alternative
to succinylcholine [9]. Sugammadex is cleared almost ex-
clusively via the kidney, with minimal or no metabolism
[10]; therefore, it is not recommended for patients with
end-stage renal failure and hemodialysis [5, 10]. However,
because sugammadex is dialyzable [11], it can be used in
hemodialysis patients. In this case report, we tested the
feasibility of rocuronium-sugammadex use for ECT in a
hemodialysis patient. In addition, we measured plasma
concentrations for the sum of sugammadex and
sugammadex-rocuronium complex and observed whether
possible residual sugammadex affected muscle relaxation
during subsequent sessions of ECT.* Correspondence: s-kurita@fch.ne.jp
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Case presentation
A 69-year-old female patient, 133 cm in height and
weighing 25 kg, was scheduled for ten ECT sessions for
severe major depression. She had a history of chronic
renal failure, and hemodialysis was induced 6 months
before consultation to the psychiatric department of
Kure Medical Center. She had a history of bronchial
asthma. Brain MRI showed brain atrophy and old fine
cerebral infarctions. She was diagnosed with depression
with a mixed type of cognitive impairment. Psychiatric
medical therapy was started, but her depressive state
worsened, and she was admitted by legal control. After
admission, she had hemodialysis three times a week,
basically on Monday, Wednesday, and Friday. Every
hemodialysis was performed for 3 h using a high-flux
membrane (FX140™, Fresenius, Germany). In spite of
medical therapy, her symptoms deteriorated. Therefore,
ten sessions of ECT were planned after obtaining in-
formed consent from her family. Because of possible
succinylcholine-induced hyperkalemia, we initially ap-
plied a rocuronium-sugammadex procedure for muscle
relaxation of ECT. We obtained informed consent on
the following anesthesia protocols from the patient’s
family and approval of our IRB (IEC201504). All sessions
of ECT were performed in the operating room. Blood
pressure, heart rate, and oxygen saturation were moni-
tored using anesthesia monitor (Datex-Ohmeda S/5™,
GE Healthcare, Finland). The adductor pollicis train of
four (TOF) ratio using kinemyography (NNT Mechano-
Sensor™, GE Healthcare, Finland) was also monitored.
We determined the appropriate doses of rocuronium
and sugammadex required for ECT during the initial four
sessions. ECT was performed once a week on Wednesday
morning, where the patient had hemodialysis in the after-
noon, and on Friday and the Monday before the next ECT
session. Before induction of anesthesia, surface electrodes
were positioned over the ulnar nerve at the wrist. The
MechanoSensor™ was attached between the thumb and
index finger with a piece of tape. Anesthesia was inducted
by propofol with a target propofol concentration in the
blood of 2 μg/mL. After automatic calibration, supramaxi-
mal TOF stimulation was measured at 20-s intervals.
Rocuronium was given with an incremental dose of 5 mg
to obtain the TOF ratio of 0 %, and assisted mask
ventilation was initiated with 100 % oxygen, followed by a
bilateral electrical stimulation of a brief-pulse wave for ap-
proximately 5 s (Thymatron System IV™, Somatic Inc.,
USA). Immediately after seizure stopped, sugammadex
was given with an incremental dose of 25 mg for antagon-
izing rocuronium to achieve recovery of the TOF ratio of
100 %. Hypertension induced by ECT was treated with
intravenous nicardipine. We titrated the doses of rocuro-
nium and sugammadex during these sessions. Throughout
these four sessions, 20 mg rocuronium and 75 mg
sugammadex were found adequate to obtain 0 % and
100 % of the TOF ratios, respectively.
During the fifth to eighth sessions, ECT was given
twice a week on Tuesday and Thursday as ordinary pro-
cedures [12]. Changes of plasma concentrations for the
sum of sugammadex and its rocuronium complex were
studied. Fixed doses of 20 mg rocuronium and 75 mg
sugammadex were given throughout the sessions. The
procedures for induction of anesthesia, muscular block-
ade, ECT, and reversal of rocuronium were the same as
in the initial four sessions. Plasma concentrations for the
sum of sugammadex and its rocuronium complex were
measured as follows: 5 mL blood samples were obtained
immediately before and after hemodialysis via a dialysis
needle on the day before the fifth ECT and the next day
after the fifth to eighth ECT. Blood samples were centri-
fuged in 2000–3000g, and 2 mL of plasma was cryopre-
served at −20 °C. Later, plasma concentrations for the
sum of sugammadex and its rocuronium complex were
determined using validated liquid chromatographic assay
methods with mass spectrometric detection at the Insti-
tute of Applied Medicine Inc., Hokkaido, Japan. The lower
limit of quantification for the assays was 0.1 μg/mL.
Changes in plasma concentrations for the sum of
sugammadex and its complex are shown in Fig. 1a, and
minimum TOF ratio immediately before electroshock is
shown in Fig. 1b. Briefly, the sum of sugammadex and its
complex concentration was 0.16 μg/mL immediately after
three sessions of hemodialysis on the day before the fifth
ECT. The values of the plasma concentrations before and
after hemodialysis on the next day of the fifth ECT were
8.2 and 3.1 μg/mL, respectively. They were 11.5 and
4.2 μg/mL for the sixth ECT, 11.1 and 4.5 μg/mL for the
seventh ECT, and 11.4 and 4.3 μg/mL for the eighth ECT.
The changes in concentrations showed that an accumula-
tion of sugammadex and its rocuronium complex did
occur. The average reduction ratio (RR) for the sum of the
sugammadex and its rocuronium complex by hemodialysis
was 61.9 %. The TOF ratios became 0 % after administra-
tion of 20 mg rocuronium in the first to fifth ECT, but
TOF ratios remained 8–14 % in the sixth to eighth ECT, in-
dicating residual free sugammadex captured rocuronium in
part and decreased the effect of rocuronium.
Ten sessions of ECT were performed without complica-
tions, and her depressive state dramatically improved. There
was no recurarization, muscular weakness, or respiratory
problems encountered after ECT during the sessions.
Discussion
Although not recommended for use in patients with se-
vere renal impairment [5, 10], sugammadex can reverse
rocuronium-induced neuromuscular blockade effectively
in such patients [13]. Our experience in this case report
showed the feasibility of rocuronium-sugammadex use
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for ECT in patients undergoing hemodialysis. However,
an accumulation of sugammadex did occur even after
two sessions of hemodialysis (Fig. 1a). Cammu et al. re-
ported that hemodialysis using a high-flux dialysis
method was effective in removing sugammadex and its
rocuronium complex in patients with severe renal
impairment [11]. In their intensive care patients, the ob-
served RR in the plasma concentrations of sugammadex
was 69 % during the first dialysis. The value of the RR
was similar to the 61.9 % observed as the average RR in the
sum of sugammadex and its rocuronium complex in our
patient. An RR of 60–70 %, however, may indicate inad-
equate removal of sugammadex and its rocuronium com-
plex in a single session or two sessions of hemodialysis. In
this case report, we confirmed that residual sugammadex
decreased the effect of the fixed dose of rocuronium given
in the subsequent ECT sessions (Fig. 1b).
The prevention of bone fractures during ECT is espe-
cially important in hemodialysis patients because of the
prevalence of osteopenia in such patients [14]. A twitch
depression of 11–25 % was reported as appropriate in one
study, but the optimal level of neuromuscular blockade
for ECT remains largely unknown [5]. In our patient, we
used a fixed dose of rocuronium and sugammadex during
the fifth to eighth ECT sessions and allowed an increase of
the TOF ratio up to 14 %. More paralysis might be safer in
order to prevent fractures, although no such complication
was encountered in our patient.
Although we confirmed that the combination of rocuro-
nium and sugammadex is a feasible alternative muscle
relaxation for ECT even in patients with hemodialysis, the
high costs of sugammadex may be a challenge economic-
ally [15]. The possibility of rocuronium- or sugammadex-
induced anaphylaxis [16, 17] and the risk of recurarization
[18] are also other concerns in the use of the rocuronium-
sugammadex combination. Further study is needed to
evaluate the risk- and cost-benefits for use of rocuronium-
sugammadex for ECT in hemodialysis patients.
Conclusions
We successfully used the rocuronium-sugammadex
procedure over eight sessions as muscle relaxation for
ECT in a hemodialysis patient. If succinylcholine is con-
traindicated, the rocuronium-sugammadex combination
may be an alternative method for muscle relaxation dur-
ing ECT in patients undergoing hemodialysis. When this
alternative procedure is used, neuromuscular monitoring
such as quantitative measurement of the TOF ratio should
be used to titrate the dose of rocuronium while consider-
ing the effect of residual sugammadex after hemodialysis.
b
a
Fig 1 a Plasma concentrations for the sum of sugammadex and sugammadex-rocuronium complex. Gray bars represent hemodialysis, and black
diamonds show the concentration before and after hemodialysis. b Minimum train of four ratio immediately before electroconvulsive therapy. HD
hemodialysis, ECT electroconvulsive therapy, TOF train of four
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